BTIG Maintains Buy on Genmab, Raises Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman maintains a Buy rating on Genmab (NASDAQ:GMAB) and raises the price target from $46 to $47.
June 27, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Kaveri Pohlman maintains a Buy rating on Genmab and raises the price target from $46 to $47.
The Buy rating and increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100